Researcher Profile

Researcher Profile

David Claxton, MD

David Claxton, MD

Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Immunotherapy
Leukemia and Lymphoma
dfc10@psu.edu

Research Interests

Dr. David Claxton has longstanding interests in leukemia biology and therapeutics. Leukemia molecular genetics and diagnostics are ongoing interests. Acute myeloid leukemia and related disorders are his principal foci. Leukemia therapeutics are particular interests, including drug development and clinical studies, blood and marrow transplantation, and clinical supportive care. He has a laboratory which has banked many samples of human leukemias and lymphomas. These are viably cryopreserved, used in studies and available to collaborators.

  • Acute Myeloid Leukemia
  • Therapeutics
  • Leukemia
  • Neoplasms
  • Genes
  • Transplants
  • Stem Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Bone Marrow
  • T-Lymphocytes
  • Drug Therapy
  • Survival

Clinical Trials

Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
Protocol for a Research Database for Hematopoietic Cell Transplantation, other Cellular Therapies and Marrow Toxic Injuries.
Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine Pre-conditioning followed by Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)(M19-063)
Biologic Studies of Experimental Anti-Cancer Therapeutics in Human Leukemia Cells
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia

Recent Publications

2022

Long, NA, Golla, U, Sharma, A & Claxton, DF 2022, 'Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications', Stem Cell Reviews and Reports, vol. 18, no. 4, pp. 1211-1226. https://doi.org/10.1007/s12015-021-10308-6
Fisher-Wellman, KH, Hagen, JT, Kassai, M, Kao, LP, Nelson, MAM, McLaughlin, KL, Coalson, HS, Fox, TE, Tan, SF, Feith, DJ, Kester, M, Loughran, TP, Claxton, DF & Cabot, MC 2022, 'Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia', FASEB Journal, vol. 36, no. 1, e22094. https://doi.org/10.1096/fj.202101194RRR
Claxton, DF 2022, 'Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment', British Journal of Haematology, vol. 198, no. 1, pp. 9-10. https://doi.org/10.1111/bjh.18174
Khokhlatchev, AV, Sharma, A, Deering, TG, Shaw, JJP, Costa-Pinheiro, P, Golla, U, Annageldiyev, C, Cabot, MC, Conaway, MR, Tan, SF, Ung, J, Feith, DJ, Loughran, TP, Claxton, DF, Fox, TE & Kester, M 2022, 'Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia', FASEB Journal, vol. 36, no. 10, e22514. https://doi.org/10.1096/fj.202200765R
Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Shah, N, Tuanquin, L, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Shike, H 2022, 'Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis', Annals of Hematology. https://doi.org/10.1007/s00277-022-05077-2
Ung, J, Tan, SF, Fox, TE, Shaw, JJP, Vass, LR, Costa-Pinheiro, P, Garrett-Bakelman, FE, Keng, MK, Sharma, A, Claxton, DF, Levine, RL, Tallman, MS, Cabot, MC, Kester, M, Feith, DJ & Loughran, TP 2022, 'Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia', Blood Reviews, vol. 55, 100950. https://doi.org/10.1016/j.blre.2022.100950
Qian, F, Arner, BE, Kelly, KM, Annageldiyev, C, Sharma, A, Claxton, DF, Paulson, RF & Prabhu, KS 2022, 'Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia', FASEB Journal, vol. 36, no. 5, e22328. https://doi.org/10.1096/fj.202200251R
Shah, N, Cioccio, J, Rakszawski, K, Zheng, H, Nickolich, M, Naik, S, Wirk, B, Rybka, W, Ehmann, C, Silar, B, Vajdic, C, Mierski, J, Zhou, S, Shike, H, Greiner, R, Brown, V, Hohl, R, Claxton, D, Mineishi, S, Minagawa, K & Tuanquin, L 2022, 'Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide', Leukemia Research, vol. 123, 106969. https://doi.org/10.1016/j.leukres.2022.106969
Pizzola, CJ, Cioccio, J, Rakszawski, KL, Nickolich, M, Ehmann, WC, Rybka, WB, Wirk, B, Naik, S, Zheng, H, Silar, B, Shike, H, Zhou, S, Mineishi, S, Minagawa, K & Claxton, DF 2022, 'Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities', Bone Marrow Transplantation, vol. 57, no. 11, pp. 1743-1745. https://doi.org/10.1038/s41409-022-01821-4
Zhao, C, Bartock, M, Jia, B, Shah, N, Claxton, DF, Wirk, B, Rakszawski, KL, Nickolich, MS, Naik, SG, Rybka, WB, Ehmann, WCC, Hohl, RJ, Valentin, J, Bernas-Peterson, M, Gerber, EM, Zimmerman, M, Mierski, JA, Mineishi, S & Zheng, H 2022, 'Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant', Journal of Hematology and Oncology, vol. 15, no. 1, 64. https://doi.org/10.1186/s13045-022-01287-3
Xu, J, Song, F, Lyu, H, Kobayashi, M, Zhang, B, Zhao, Z, Hou, Y, Wang, X, Luan, Y, Jia, B, Stasiak, L, Wong, JHY, Wang, Q, Jin, Q, Jin, Q, Fu, Y, Yang, H, Hardison, RC, Dovat, S, Platanias, LC, Diao, Y, Yang, Y, Yamada, T, Viny, AD, Levine, RL, Claxton, D, Broach, JR, Zheng, H & Yue, F 2022, 'Subtype-specific 3D genome alteration in acute myeloid leukaemia', Nature, vol. 611, no. 7935, pp. 387-398. https://doi.org/10.1038/s41586-022-05365-x
Ehudin, MA, Golla, U, Trivedi, D, Potlakayala, SD, Rudrabhatla, SV, Desai, D, Dovat, S, Claxton, D & Sharma, A 2022, 'Therapeutic Benefits of Selenium in Hematological Malignancies', International journal of molecular sciences, vol. 23, no. 14, 7972. https://doi.org/10.3390/ijms23147972

2021

Jia, B, Zhao, C, Bayerl, M, Shike, H, Claxton, DF, Ehmann, WC, Mineishi, S, Schell, TD, Zheng, P, Zhang, Y, Shultz, LD, Prabhu, KS, Paulson, RF & Zheng, H 2022, 'A novel clinically relevant graft-versus-leukemia model in humanized mice', Journal of Leukocyte Biology, vol. 111, no. 2, pp. 427-437. https://doi.org/10.1002/JLB.5AB0820-542RR
Advani, AS, Larsen, E, Laumann, K, Luger, SM, Liedtke, M, Devidas, M, Chen, Z, Yin, J, Foster, MC, Claxton, D, Coffan, K, Tallman, MS, Appelbaum, FR, Erba, H, Stone, RM, Hunger, SP, McNeer, JL, Loh, ML, Raetz, E, Winick, N, Carroll, W, Larson, RA & Stock, W 2021, 'Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia', Blood Advances, vol. 5, no. 2, pp. 504-512. https://doi.org/10.1182/bloodadvances.2020002439
Golla, U, Ehudin, MA, Annageldiyev, C, Zeng, Z, Bastihalli Tukaramrao, D, Tarren, A, Date, AA, Elcheva, I, Berg, A, Amin, S, Loughran, TP, Kester, M, Desai, D, Dovat, S, Claxton, D & Sharma, A 2021, 'Dj4 targets the rho-associated protein kinase pathway and attenuates disease progression in preclinical murine models of acute myeloid leukemia', Cancers, vol. 13, no. 19, 4889. https://doi.org/10.3390/cancers13194889
Zhu, G, Luo, H, Feng, Y, Guryanova, OA, Xu, J, Chen, S, Lai, Q, Sharma, A, Xu, B, Zhao, Z, Feng, R, Ni, H, Claxton, D, Guo, Y, Mesa, RA, Qiu, Y, Yang, FC, Li, W, Nimer, SD, Huang, S & Xu, M 2021, 'HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia', Nature communications, vol. 12, no. 1, 1956. https://doi.org/10.1038/s41467-021-22095-2
Shah, N, Rakszawski, K, Nickolich, M, Ehmann, C, Wirk, B, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Mackey, G, Greiner, R, Brown, V, Claxton, D, Mineishi, S & Minagawa, K 2021, 'Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion', Annals of Hematology, vol. 100, no. 10, pp. 2585-2592. https://doi.org/10.1007/s00277-021-04616-7
List, AF, Sun, Z, Verma, A, Bennett, JM, Komrokji, RS, McGraw, K, Maciejewski, J, Altman, JK, Cheema, PS, Claxton, DF, Luger, SM, Mattison, RJ, Wassenaar, TR, Artz, AS, Schiffer, CA, Litzow, MR & Tallman, MS 2021, 'Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 9, pp. 1001-1009. https://doi.org/10.1200/JCO.20.01691
Klink, M, Rahman, MA, Song, C, Dhanyamraju, PK, Ehudin, M, Ding, Y, Steffens, S, Bhadauria, P, Iyer, S, Aliaga, C, Desai, D, Huang, S, Claxton, D, Sharma, A & Gowda, C 2021, 'Mechanistic basis for in vivo therapeutic efficacy of ck2 inhibitor cx-4945 in acute myeloid leukemia', Cancers, vol. 13, no. 5, 1127, pp. 1-21. https://doi.org/10.3390/cancers13051127
Kantarjian, HM, Begna, KH, Altman, JK, Goldberg, SL, Sekeres, MA, Strickland, SA, Arellano, ML, Claxton, DF, Baer, MR, Gautier, M, Berman, E, Seiter, K, Solomon, SR, Schiller, GJ, Luger, SM, Butrym, A, Gaidano, G, Thomas, XG, Montesinos, P, Rizzieri, DA, Quick, DP, Venugopal, P, Gaur, R, Maness, LJ, Kadia, TM, Ravandi, F, Buyse, ME & Chiao, JH 2021, 'Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)', Cancer, vol. 127, no. 23, pp. 4421-4431. https://doi.org/10.1002/cncr.33828
Gvozdjan, K, Casey, H, Mowery, C, Kumer, L, Fisher, C, Tyler, J, Bayerl, MG, Malysz, J, Naik, S, Rybka, W, Ehmann, C, Claxton, D, Mineishi, S, Baker, M, Hong, Z & Shike, H 2021, 'Unexpected Short-Tandem-Repeat Patterns in Post-Transplant Chimerism Testing: Investigation of 3 Cases with Help from Forensic Science', Laboratory Medicine, vol. 51, no. 6, pp. 635-641. https://doi.org/10.1093/LABMED/LMAA022

2020

Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043
Yan, B, Claxton, D, Huang, S & Qiu, Y 2020, 'AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy', Experimental Hematology, vol. 87, pp. 13-19. https://doi.org/10.1016/j.exphem.2020.06.003
Pearson, JM, Tan, SF, Sharma, A, Annageldiyev, C, Fox, TE, Abad, JL, Fabrias, G, Desai, D, Amin, S, Wang, HG, Cabot, MC, Claxton, DF, Kester, M, Feith, DJ & Loughran, TP 2020, 'Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemia', Molecular Cancer Research, vol. 18, no. 3, pp. 352-363. https://doi.org/10.1158/1541-7786.MCR-19-0619
Gebru, MT, Atkinson, JM, Young, MM, Zhang, L, Tang, Z, Liu, Z, Lu, P, Dower, CM, Chen, L, Annageldiyev, C, Sharma, A, Kawasawa, YI, Zhao, Z, Miller, BA, Claxton, DF & Wang, HG 2020, 'Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia', Blood, vol. 136, no. 9, pp. 1067-1079. https://doi.org/10.1182/blood.2019003124
Tsukamoto, AS, Van Den Berg, D, Reading, C, Tong, J, Murray, L, Carella, A, Frassoni, F, Snyder, D, Herzig, G, Gorin, C, Laporte, J, Negrin, R, Blume, R, Cunningham, I, Claxton, D, Deisseroth, A & Hoffman, R 2020, Isolation of both normal and leukemic cells within the hematopoietic stem cell compartment of chronic myelogenous leukemia mobilized peripheral blood. in Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies. Taylor and Francis, pp. 27-32. https://doi.org/10.4324/9781003077343-4
Pagel, JM, Othus, M, Garcia-Manero, G, Fang, M, Radich, JP, Rizzieri, DA, Marcucci, G, Strickland, SA, Litzow, MR, Lynn Savoie, M, Spellman, SR, Confer, DL, Chell, JW, Brown, M, Medeiros, BC, Sekeres, MA, Lin, TL, Uy, GL, Powell, BL, Bayer, RL, Larson, RA, Stone, RM, Claxton, D, Essell, J, Luger, SM, Mohan, SR, Moseley, A, Erba, HP & Appelbaum, FR 2020, 'Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia', JCO Oncology Practice, vol. 16, no. 6, pp. E464-E475. https://doi.org/10.1200/JOP.19.00133
Annageldiyev, C, Tan, SF, Thakur, S, Dhanyamraju, PK, Ramisetti, SR, Bhadauria, P, Schick, J, Zeng, Z, Sharma, V, Dunton, W, Dovat, S, Desai, D, Zheng, H, Feith, DJ, Loughran, TP, Amin, S, Sharma, AK, Claxton, D & Sharma, A 2020, 'The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia', Frontiers in Oncology, vol. 10, 393. https://doi.org/10.3389/fonc.2020.00393
Annageldiyev, C, Gowda, K, Patel, T, Bhattacharya, P, Tan, SF, Iyer, S, Desai, D, Dovat, S, Feith, DJ, Loughran, TP, Amin, S, Claxton, D & Sharma, A 2020, 'The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia', Haematologica, vol. 105, no. 3, pp. 687-696. https://doi.org/10.3324/haematol.2018.212886

2019

Stock, W, Luger, SM, Advani, AS, Yin, J, Harvey, RC, Mullighan, CG, Willman, CL, Fulton, N, Laumann, KM, Malnassy, G, Paietta, E, Parker, E, Geyer, S, Mrózek, K, Bloomfield, CD, Sanford, B, Marcucci, G, Liedtke, M, Claxton, DF, Foster, MC, Bogart, JA, Grecula, JC, Appelbaum, FR, Erba, H, Litzow, MR, Tallman, MS, Stone, RM & Larson, RA 2019, 'A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403', Blood, vol. 133, no. 14, pp. 1548-1559. https://doi.org/10.1182/blood-2018-10-881961
Tan, SF, Dunton, W, Liu, X, Fox, TE, Morad, SAF, Desai, D, Doi, K, Conaway, MR, Amin, S, Claxton, DF, Wang, HG, Kester, M, Cabot, MC, Feith, DJ & Loughran, TP 2019, 'Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation', Journal of Lipid Research, vol. 60, no. 6, pp. 1078-1086. https://doi.org/10.1194/jlr.M091876
Patel, TN, Madhunapantula, SRV, Annageldiyev, C, Claxton, D & Sharma, A 2019, Animal mouse models of acute myeloid leukemia. in A Azmi & RM Mohammad (eds), Animal Models in Cancer Drug Discovery. Academic Press, pp. 419-438. <https://www.sciencedirect.com/book/9780128147047/animal-models-in-cancer-drug-discovery>
Kao, LP, Morad, SAF, Davis, TS, MacDougall, MR, Kassai, M, Abdelmageed, N, Fox, TE, Kester, M, Loughran, TP, Abad, JL, Fabrias, G, Tan, SF, Feith, DJ, Claxton, DF, Spiegel, S, Fisher-Wellman, KH & Cabot, MC 2019, 'Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells', Journal of Lipid Research, vol. 60, no. 9, pp. 1590-1602. https://doi.org/10.1194/jlr.RA119000251
Kong, Y, Jia, B, Zhao, C, Claxton, DF, Sharma, A, Annageldiyev, C, Fotos, JS, Zeng, H, Paulson, RF, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients', Journal of Hematology and Oncology, vol. 12, no. 1, 40. https://doi.org/10.1186/s13045-019-0728-3
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Pu, JJ, Poulose, J, Malysz, J, Zhu, J, Fanburg-Smith, JC, Claxton, DF & Bayerl, MG 2019, 'Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study', British Journal of Haematology, vol. 186, no. 5, pp. e130-e133. https://doi.org/10.1111/bjh.15967
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684. https://doi.org/10.1111/bjh.16228
Kempin, S, Sun, Z, Kay, NE, Paietta, EM, Mazza, JJ, Ketterling, RP, Frankfurt, O, Claxton, DF, Saltzman, JN, Srkalovic, G, Callander, NS, Gross, G & Tallman, MS 2019, 'Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)', Acta Haematologica, vol. 142, no. 4, pp. 224-232. https://doi.org/10.1159/000500164
Spurgeon, SE, Sharma, K, Claxton, DF, Ehmann, C, Pu, J, Shimko, S, Stewart, A, Subbiah, N, Palmbach, G, LeBlanc, F, Latour, E, Chen, YY, Mori, M, Hasanali, Z & Epner, EM 2019, 'Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma', British Journal of Haematology, vol. 186, no. 6, pp. 845-854. https://doi.org/10.1111/bjh.16008
Barth, BM, Wang, W, Toran, PT, Fox, TE, Annageldiyev, C, Ondrasik, RM, Keasey, NR, Brown, TJ, Devine, VG, Sullivan, EC, Cote, AL, Papakotsi, V, Tan, SF, Shanmugavelandy, SS, Deering, TG, Needle, DB, Stern, ST, Zhu, J, Liao, J, Viny, AD, Feith, DJ, Levine, RL, Wang, HG, Loughran, TP, Sharma, A, Kester, M & Claxton, DF 2019, 'Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia', Blood Advances, vol. 3, no. 17, pp. 2598-2603. https://doi.org/10.1182/bloodadvances.2018021295
Cioccio, J & Claxton, D 2019, 'Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases', Expert Opinion on Investigational Drugs, vol. 28, no. 4, pp. 337-349. https://doi.org/10.1080/13543784.2019.1584610

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)